Piper Sandler sets USD 457 target for Amgen stock

Published on 10/06/2026 at 17:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Piper Sandler kept Buy and set a USD 457.00 target on October 5, 2026. Amgen stock had a USD 401.39 consensus target as revenue reached USD 10.05 billion.

Isometrische 3D-Illustration einer biopharmazeutischen Wertschöpfungskette von Labor bis Vertrieb mit Bioreaktoren — Amgen Inc. (ISIN US0311621009) dargestellt als isometrisches 3D-Diagramm der biopharmazeutischen Wertschöpfungskette von Labor bis Versand, Illustration mit AI erstellt.

Amgen (ISIN US0311621009) has a USD 457.00 price target from Piper Sandler, which reiterated a Buy rating on October 5, 2026, according to Markets Insider. The analyst view arrives as Amgen combines fresh clinical progress with a second-quarter earnings base that gives the valuation discussion a concrete anchor.

Target stays above consensus

Piper Sandler's USD 457.00 target sits above the USD 401.39 consensus target cited by Markets Insider, creating a USD 55.61 gap between the two reference points. The same report said the analyst maintained a Buy rating, while the consensus view was Moderate Buy.

A broader analyst survey presents a more balanced picture. MarketBeat reported a Hold consensus and an average target of USD 385.25 on October 6, 2026, alongside targets ranging from USD 380.00 from Barclays to USD 457.00 from Piper Sandler.

Second-quarter figures provide support

Amgen's second-quarter 2026 revenue reached USD 10.05 billion, while diluted earnings per share were USD 4.37, according to the finance statement for the period ended June 30, 2026. Revenue increased from USD 8.62 billion in the first quarter of 2026, and operating cash flow rose from USD 2.19 billion to USD 4.00 billion across those two reported quarters.

Amgen listed positive topline phase 3 results for dazodalibep in moderate-to-severe systemic Sjogren's disease on September 22, 2026. That clinical update adds a pipeline dimension to the earnings story, although the analyst targets still show a wide range of views on how much future progress is reflected in the stock.

Nasdaq range frames the valuation

AMGN was at USD 401.24 on Nasdaq at 11:06 a.m. EDT on October 6, 2026. The stock's USD 288.00 to USD 447.03 52-week range places the quote below the yearly high, while market capitalization stood at USD 216.6 billion at the same timestamp.

For investors, the central comparison is therefore numerical: the USD 457.00 Piper Sandler target is above both the USD 401.39 consensus target and the latest Nasdaq quote, while the USD 385.25 MarketBeat average target is lower. The next catalyst is the continuing read-through from Amgen's clinical pipeline and its recent quarterly performance.

Amgen stock faces a split target picture

Amgen combines USD 10.05 billion in second-quarter revenue with a USD 457.00 bullish target from Piper Sandler, but the USD 385.25 consensus average shows that analysts do not assign the same value to the pipeline and earnings outlook.